Shift Bioscience

Shift is chasing the single most valuable prize in cellular rejuvenation — a way to reset a cell's age without the cancer risk of full reprogramming — and in June 2025 it reported exactly that: SB000, a single-gene intervention that reversed cellular aging across multiple germ layers with efficacy the company compared to the full Yamanaka-factor cocktail, at both the methylome and transcriptome levels, without evidence of pluripotency. If that result holds, it is a genuine breakthrough: a one-gene rejuvenation factor is dramatically simpler to deliver as a therapy than the multi-factor OSKM cocktails the field has relied on, and it strips out the tumorigenic teratoma risk that has kept in-vivo reprogramming perpetually "five years away." The discovery is not luck but process — Shift's narrow-AI platform, built on proprietary multiomic datasets and its AC3 aging clock (trained across ages one to 87), screened roughly 1,500 candidate genes to surface SB000 and continues to generate further candidates, giving Shift a repeatable engine rather than a one-off hit. Backed by BGF, F-Prime Capital, Kindred Capital, and Jonathan Milner (the Abcam founder) with ~$18M raised, and operating out of Cambridge's Gurdon Institute — the birthplace of reprogramming science — Shift is a capital-efficient team sitting on a potentially category-defining, safer path to rejuvenation therapeutics.